Bispecific antibody
PreclinicalSmall molecule
Bispecific antibody is one of 28 small molecule programs targeting Lymphoma. It is currently in Preclinical.
1
Indications
2
Total Trials
2
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Velban
EEastern Cooperative Oncology Group
Preclinical
Zofran
NovartisPreclinical
Wellcovorin
GGlaxo Dba Glaxosmithkline
Preclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
PEG-Intron
Merck & Co.Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Rhg-CSF
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bispecific antibody. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSung-Soo Park